4D Molecular Therapeutics
Most recent annual filing: 2026-03-18
- RGX-314 AbbVie Ph3 readout2026RGX-314 AbbVie Ph3 readout, 2026, notable
- 4D-150 DME readout2H 20264D-150 DME readout, 2H 2026, notable
- 4D-150 DME Ph3 start3Q 20264D-150 DME Ph3 start, 3Q 2026, routine
- 4D-710 AEROW Ph1 readout4Q 20264D-710 AEROW Ph1 readout, 4Q 2026, notable
- Ixo-vec ARTEMIS Ph3 topline1Q 2027Ixo-vec ARTEMIS Ph3 topline, 1Q 2027, material
- 4D-150 4FRONT-1 AMD Ph3 topline2Q 20274D-150 4FRONT-1 AMD Ph3 topline, 2Q 2027, thesis-defining
- 4D-150 4FRONT-2 AMD Ph3 topline2H 20274D-150 4FRONT-2 AMD Ph3 topline, 2H 2027, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
4D-175
Gene Therapy Target: complement factor H
4D-710
Gene Therapy Target: CFTR
4D-725
Gene Therapy Target: alpha-1 antitrypsin
Technology platforms
Therapeutic Vector Evolution
Directed evolution platform applied in non-human primate models to generate diverse libraries of ~1 billion synthetic AAV capsid sequences and select customized evolved vectors targeting specific tissues; disease focus includes retina and lung diseases
Biotech Distilled coverage (3)
- 2026-08-14 UPDATE: 4D Molecular Therapeutics (FDMT) - The Runway Math Just Got Answered 🔒 Paid
- 2026-07-24 UPDATE: 4D Molecular Therapeutics (FDMT) - The Data Landed Clean, The Stock Bled Anyway 🔒 Paid
- 2026-07-03 4D Molecular Therapeutics (FDMT) — Scientific Deep Dive for 4D-150 and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.